 | |
| Clinical data | |
|---|---|
| Other names | HL-085 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H12F2IN3O3S |
| Molar mass | 491.25 g·mol−1 |
Tunlametinib is a pharmaceutical drug for the treatment of cancer. It is an inhbitor ofmitogen-activated protein kinase kinase.[1]
In China, tunlametinib was approved in 2024 for the treatment of patients withNRAS-mutated advancedmelanoma who were previously treated with aPD-1/PD-L1 targeting agent.[2][3]
It is also being studied for use in combination withvemurafenib in patients with advanced BRAF V600-mutant solid tumors.[4]
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
